Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. This evidence concerns the gene SLC25A1 and metabolic dysfunction-associated steatohepatitis.